Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ramatroban - KARE Biosciences

X
Drug Profile

Ramatroban - KARE Biosciences

Alternative Names: KAR-101

Latest Information Update: 19 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KARE Biosciences
  • Class Anti-inflammatories; Antiallergics; Antifibrotics; Antihypertensives; Antivirals; Carbazoles; Skin disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action Prostaglandin D2 receptor antagonists; Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III COVID-19 pneumonia; COVID-19 respiratory infection
  • Preclinical Contact dermatitis; Lung disorders; Myocardial infarction; Pneumonia; Pulmonary arterial hypertension; Sepsis
  • Research Dengue; Idiopathic pulmonary fibrosis; Respiratory syncytial virus infections; Sickle cell anaemia

Most Recent Events

  • 19 Jun 2023 KARE Biosciences plans a RAMBAN-2 clinical trial for COVID-2019 respiratory infections (KARE Biosciences pipeline, June 2023)
  • 19 Jun 2023 KARE Biosciences plans a RAMBAN-3 clinical trial for COVID-2019 respiratory infections (KARE Biosciences pipeline, June 2023)
  • 02 Apr 2023 KARE Biosciences released the preclinical data in COVID-19 infection and myocardial infraction (before April 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top